These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2698243)

  • 21. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Kahán Z
    Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
    [No Abstract]   [Full Text] [Related]  

  • 22. Is radiation necessary for older women with breast cancer? Once the tumor is removed, tamoxifen by itself is effective, but for younger women it's a very different story.
    Health News; 2004 Dec; 10(12):6-7. PubMed ID: 15645562
    [No Abstract]   [Full Text] [Related]  

  • 23. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct antiproliferative effect of triptorelin on human breast cancer cells.
    Marini L; Iacopino F; Schinzari G; Robustelli della Cuna FS; Mantovani G; Sica G
    Anticancer Res; 1994; 14(5A):1881-5. PubMed ID: 7847821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
    Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
    Illiger HJ
    Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
    [No Abstract]   [Full Text] [Related]  

  • 29. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
    Pritchard KI
    Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
    [No Abstract]   [Full Text] [Related]  

  • 33. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
    Altundag K; Altundag O
    J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hormone therapy in breast cancer].
    Rouëssé J
    Chirurgie; 1994-1995; 120(6-7):330-7. PubMed ID: 7768120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary multiple neoplasm of the endometrium and adjuvant hormone therapy in patients with breast cancer].
    Bakhidze EV; Maksimov SIa; Barash NIu; Berstein LM; Semiglazov VF; Sheĭko EV; Novik VI
    Vopr Onkol; 1998; 44(2):170-4. PubMed ID: 9615821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-aromatase acting drugs].
    Diedrich K
    Krankenpfl J; 2005; 43(4-6):150-1. PubMed ID: 16171094
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
    Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
    Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hormones in gynecologic oncology].
    Maass H
    Arch Gynecol Obstet; 1989; 245(1-4):466-73. PubMed ID: 2802734
    [No Abstract]   [Full Text] [Related]  

  • 40. Tamoxifen equivalent to oophorectomy in advanced breast Ca.
    Yonemoto RE
    Oncology (Williston Park); 1989 Feb; 3(2):17-8. PubMed ID: 2488259
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.